Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Observational Study
    Online & In-Person

    Bridge2AI-Voice as a Biomarker of Health

    What is this Study about?

    The aim of this study is to develop a large, ethically sources, and diverse database of voice recordings to determine whether voice has biomarkers for particular disease categories, including neurological and neurodevelopmental conditions. The data that is collected will be used to develop a full open-access database to fuel artificial intelligence research related to voice.

    Eligibility Criteria

    • Between ages of 44-85
    • Able to read, write, speak, and understand English
    • Be diagnosed with one of the following conditions:
      • Alzheimer’s disease
      • Parkinson’s disease
      • Amyotrophic Lateral Sclerosis
      • Mild Cognitive Impairment, or other types of dementia
    • Consent to provide a voice/speech sample

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    Nabilone for Agitation Blinded Intervention Trial (NAB-IT)

    What is this Study about?

    It is expected that the information collected during this study will be used in analyses and will be published/presented to the scientific community at meetings and in journals. This information may also be used as part of a submission to regulatory authorities around the world to support the approval of the study intervention for agitation in AD.

    Eligibility Criteria

    You are eligible to participate if you meet the following criteria:

    • Age ≥ 55; females must be post-menopausal

    • DSM-5 criteria for Major Neurocognitive Disorder due to AD; multiple etiologies (AD and vascular)

    • sMMSE ≤ 24

    • Clinically significant agitation based on IPA definition

    • Stable cognition-enhancing medication for at least 3 months prior to study enrolment

    • Availability of a caregiver to accompany participant to study visits and to participate in the study

    • Ability to speak English

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction in Alzheimer's Disease

    What is this Study about?

    Our study titled "Investigating the Role of Quantitative Susceptibility Mapping and Oxygen Extraction Fraction as Advanced Neuroimaging Biomarkers in Alzheimer's Disease" aims to develop non-invasive diagnostic biomarkers for Alzheimer's Disease (AD). We focus on evaluating the potential of QSM and OEF to differentiate between AD, Mild Cognitive Impairment (MCI), and Cognitively Unimpaired populations and to predict amyloid and tau pathology, using a Systems Biology approach. Leveraging the McGill University's TRIAD cohort, the study utilizes advanced imaging and machine learning to predict amyloid and tau presence, which could transform AD diagnostics and treatment. Methodologically, it involves preprocessing neuroimaging data and employing machine learning classifiers to analyze these features. The anticipated outcomes include validating QSM and OEF as non-invasive biomarkers for AD, establishing their correlation with amyloid and tau proteins, and developing predictive models for clinical decision-making, potentially resulting in significant advancements in AD diagnostics.

    Eligibility Criteria

    Are a member of the TRIAD cohort at McGill University, falling within one of the following categories: young control, cognitively unimpaired, mild cognitive impairment, or Alzheimer's Disease.

    Are willing and able to undergo advanced neuroimaging techniques including MRI and PET without contraindications.

    Have not had any significant neurological conditions (other than AD for the AD group) that might interfere with the results of the study.

    Have no metal implants, devices, or other conditions that may contraindicate or distort MRI imaging.

    Are not currently participating in other clinical trials or studies that involve interventions which might interfere with the results of this study.

    Are able and willing to provide informed consent for participation in the study or have a legally authorized representative who can do so.

    Do not have a history of substance abuse or other conditions that might confound the imaging and cognitive data.

    Have not undergone any significant head trauma or surgery in the past 6 months.

    Are not pregnant or planning to become pregnant during the duration of the study.

    Are willing to comply with all study-related procedures, imaging sessions, and follow-up evaluations.

    Ability to speak English and French

    Recruitment End Date

    Find Out More